Heart Attack (Myocardial Infarction) News and Research

RSS

A Heart Attack (Myocardial Infarction) occurs when blood flow to a section of heart muscle becomes blocked. If the flow of blood isn’t restored quickly, the section of heart muscle becomes damaged from lack of oxygen and begins to die.

Heart attack is a leading killer of both men and women in the United States. But fortunately, today there are excellent treatments for heart attack that can save lives and prevent disabilities. Treatment is most effective when started within 1 hour of the beginning of symptoms. Heart attacks occur most often as a result of a condition called coronary artery disease (CAD). In CAD, a fatty material called plaque (plak) builds up over many years on the inside walls of the coronary arteries (the arteries that supply blood and oxygen to your heart). Eventually, an area of plaque can rupture, causing a blood clot to form on the surface of the plaque. If the clot becomes large enough, it can mostly or completely block the flow of oxygen-rich blood to the part of the heart muscle fed by the artery.

Anti-clotting action of clopidogrel (Plavix) reduced by common heartburn drugs

The anti-clotting action of the medication clopidogrel (Plavix) can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50% increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses, according to a new study presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual Scientific Sessions.

6 May 2009

Results from study comparing safety and efficacy of drug-eluting stents and bare-metal stents

The Cardiovascular Research Foundation (CRF) announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published today in The New England Journal of Medicine.

6 May 2009

Research shows why certain atherosclerotic lesions can turn deadly

A common misconception about arterial plaque is that it inevitably leads to a heart attack or a stroke. New research at Columbia University Medical Center, however, sheds light on why so few plaques in any given individual actually cause a problem. Furthermore, the research has identified a key protein that may promote the conversion from benign to dangerous plaques.

5 May 2009

Arrythmia associated with heart attacks linked to higher risk of death

Heart attack patients who develop serious arrhythmia in connection with procedures to open blocked arteries face a significantly higher risk of death for several months after the procedure, when compared to similar patients who do not develop such complications, according to new research from Duke University Medical Center.

5 May 2009

Drugs designed to tackle endoplasmic reticulum stress might be useful in treating heart disease

Researchers say they have evidence to explain what separates your average blood vessel plaque from those that are at high risk for triggering the development of dangerous - even fatal - blood clots.

5 May 2009

New, more effective and less costly method for testing drugs for potential toxicity

Adverse reactions to drugs represent one of the leading causes of death in the United States. But there may be a way to predict who is most likely to suffer a toxic side effect to a drug before they have even taken it.

4 May 2009

Out-of-pocket costs reduce patients' willingness to start treatment for their chronic illnesses

Patients newly diagnosed with hypertension, diabetes or high cholesterol are significantly more likely to delay initiating recommended drug treatment if they face higher co-payments for medications, according to a new RAND Corporation study.

30 Apr 2009

Excessive increase in heart rate before exercise doubles risk of sudden cardiac death in later life

French researchers have discovered a simple and cheap method of predicting who is at greater risk of dying suddenly and unexpectedly from a heart attack.

30 Apr 2009

Arterial disease of the leg frequently overlooked in patients with heart disease

Peripheral arterial disease (PAD) of the legs, in which the arteries become blocked with plaque and blood supply to the legs is reduced, affects eight million people in the U.S. Early detection of PAD is important because it can limit the ability to walk and exercise, it may place patients at greater risk for limb loss and it increases the chance of having a heart attack or stroke.

30 Apr 2009

Urine proteome pattern may predict coronary artery disease

Proteome analysis, a screening requiring only a patient's urine specimen, shows promise as a reliable and noninvasive way to diagnose atherosclerosis and coronary artery disease in the future, according to research presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology Annual Conference 2009.

30 Apr 2009

New findings on COX-2 inhibitor side effects

In searching for a simple way to identify individuals with smoking-related lung injury, scientists at Weill Cornell Medical College have stumbled upon a potential explanation for why the class of pain-relievers known as COX-2 inhibitors increases the risk of heart problems among users.

29 Apr 2009

New hope for potential heart attack victims

Twenty percent of American deaths each year are caused by heart attack or angina, sometimes without any warning.

27 Apr 2009

High blood pressure, diabetes and increased carotid artery wall thickness means increased risk of stroke

Increased carotid artery wall thickness (CAWT), which can cause heart attack and stroke in many patients, is significantly related to diabetes and hypertension, according to a study performed at A.O.U. in Cagliari Sardegna, Italy (Chairman, Professor Giorgio Mallarini).

23 Apr 2009

Lilly granted preliminary injunction to prevent launch of generic Raloxifene

Eli Lilly and Company has announced that the U.S. District Court for the Southern District of Indiana today issued a preliminary injunction to prevent the launch of a generic version of Lilly's medicine Evista (raloxifene HCl tablets) by Teva Pharmaceuticals until the Court renders its final ruling.

22 Apr 2009